Literature DB >> 6949877

Clinical evaluation of NCA in patients with chronic myelocytic leukemia.

B Wahren, G Gahrton, U Rudén, S Hammarström.   

Abstract

NCA, a normal colon and granulocyte antigen, which has been found in large amounts in myelocytes and metamyelocytes and in smaller amounts in neutrophil granulocytes, was studied in 50 CML patients in various stages of the disease. Radioimmunoassay was used to demonstrate NCA in serum. Untreated CML patients had a mean level of 732 micrograms NCA/l, poorly controlled patients 421 micrograms/l and well-controlled patients 160 mu/l. These values differ significantly from the mean of healthy persons, which was 71 micrograms NCA/l. The serum NCA levels were related to the number of maturing myeloid cells in blood, and to the clinical course in the chronic phase of CML. In blast crisis low values with a mean of 109 micrograms NCA/l was found. Patients with ANLL had a low mean level, 50 micrograms/l. Low levels of NCA could not be attributed to antibodies to NCA. NCA is a normal myeloid differentiation antigen. Despite this, its occurrence in serum in leukemic patients differs from normal. This probably has to do with the abnormal amount as well as the release of NCA by leukemic maturing myeloid cells.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6949877     DOI: 10.1002/ijc.2910290203

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  4 in total

Review 1.  Recent advances in bone marrow scanning.

Authors:  S N Reske
Journal:  Eur J Nucl Med       Date:  1991

2.  Expression of nonspecific cross-reacting antigen species in myeloid leukemic patients and healthy subjects.

Authors:  A Noworolska; A Harłozińska; F Buchegger; B Lawińska; R Richter
Journal:  Blut       Date:  1989-02

3.  Serum NCA in bone marrow transplant recipients and its metabolism.

Authors:  F Gadler; B Wahren
Journal:  Med Oncol Tumor Pharmacother       Date:  1985

4.  An investigation of factors influencing serum NCA (non-specific cross-reacting antigen) level in patients with chronic myeloid leukaemia.

Authors:  N Frénoy; M Ben-Bunant; C Berruel; J A Child; M C Gendron; J L Missett; E Razafimahaleo; P Burtin
Journal:  Br J Cancer       Date:  1982-11       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.